Hsbc Global Res Upgrades Moderna (NASDAQ:MRNA) to Strong-Buy

Moderna (NASDAQ:MRNA) was upgraded by analysts at Hsbc Global Res from a “hold” rating to a “strong-buy” rating in a note issued to investors on Monday,Zacks.com reports.

Other equities research analysts have also recently issued reports about the stock. TD Cowen cut their price target on shares of Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a research report on Friday, September 13th. HSBC raised Moderna from a “hold” rating to a “buy” rating and set a $58.00 price target for the company in a research report on Monday. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $75.00 price target on shares of Moderna in a research report on Thursday, September 19th. Wolfe Research assumed coverage on Moderna in a report on Friday. They issued an “underperform” rating and a $40.00 price objective for the company. Finally, Deutsche Bank Aktiengesellschaft raised shares of Moderna from a “sell” rating to a “hold” rating and decreased their target price for the company from $85.00 to $80.00 in a research note on Wednesday, August 7th. Three investment analysts have rated the stock with a sell rating, twelve have given a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $86.33.

Moderna Stock Performance

Shares of Moderna stock opened at $39.51 on Monday. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. The firm has a market cap of $15.20 billion, a price-to-earnings ratio of -6.79 and a beta of 1.69. The stock’s 50-day moving average is $58.56 and its 200-day moving average is $96.68. Moderna has a one year low of $35.80 and a one year high of $170.47.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. The firm had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The business’s revenue was up 3.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.39) EPS. Equities analysts predict that Moderna will post -9.43 earnings per share for the current fiscal year.

Insider Transactions at Moderna

In related news, CFO James M. Mock sold 715 shares of the company’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the transaction, the chief financial officer now directly owns 9,505 shares in the company, valued at approximately $571,440.60. This represents a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last quarter, insiders have sold 2,930 shares of company stock worth $217,170. Company insiders own 15.20% of the company’s stock.

Institutional Trading of Moderna

A number of institutional investors have recently bought and sold shares of the business. Ashton Thomas Private Wealth LLC bought a new position in shares of Moderna during the second quarter worth approximately $26,000. Family Firm Inc. bought a new position in Moderna during the 2nd quarter worth $33,000. Bank & Trust Co acquired a new position in Moderna in the 2nd quarter valued at $36,000. Hanseatic Management Services Inc. bought a new stake in shares of Moderna during the 2nd quarter valued at $48,000. Finally, Plato Investment Management Ltd grew its holdings in shares of Moderna by 230.4% during the 2nd quarter. Plato Investment Management Ltd now owns 413 shares of the company’s stock worth $49,000 after purchasing an additional 288 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.